PILAR OBAT · PRIORITAS 1
65 obat kandidat HTA paling kuat untuk Indonesia.
Obat yang ada di NICE Drug HTA DAN WHO Essential Medicines List, namun BELUM di Fornas Indonesia. Dua sumber bukti internasional independen menyebut, Indonesia belum mengadopsi. Ini argumen advokasi paling kuat: cost-effective di NHS UK + diakui WHO essential = wajib dipertimbangkan untuk Fornas.
65
Obat Prioritas 1
248
Total NICE appraisals tersebar
7
Kelas ATC yang terdampak
✗
Coverage Fornas (definisi P1)
Kriteria Prioritas 1 — obat memenuhi semua tiga syarat:
- ada di NICE Drug HTA (TA atau HST) sebagai technology yang sudah dievaluasi cost-effectiveness-nya
- ada di WHO Essential Medicines List (model international essential drug list)
- BELUM ada di Fornas Indonesia
Logic: jika dua institusi independen — NICE (UK HTA gold standard) + WHO EML (international consensus) — sama-sama menyebut, dan Indonesia belum punya, maka ini gap advokasi yang paling solid secara evidence.
Distribusi
Per kelas ATC anatomi
| Kelas ATC L1 | Jumlah | % dari priority | |
|---|---|---|---|
| Antineoplastic and immunomodulating agents | 45 | 69.2% | cladribine, azacitidine, dasatinib, ... |
| Alimentary tract and metabolism | 6 | 9.2% | liraglutide, semaglutide, dapagliflozin, ... |
| Nervous system | 6 | 9.2% | erenumab, galcanezumab, fremanezumab, ... |
| Blood and blood forming organs | 3 | 4.6% | apixaban, edoxaban, erythropoiesis-stimulating agents |
| Antiinfectives for systemic use | 3 | 4.6% | oseltamivir, sofosbuvir and ledipasvir, glecaprevir and pibrentasvir |
| Musculo-skeletal system | 1 | 1.5% | risdiplam |
| Respiratory system | 1 | 1.5% | ivacaftor |
Kandidat advokasi paling kuat
Top 8 dengan NICE appraisal terbanyak
- L01FF02pembrolizumabAntineoplastic and immunomodulating agents · source: NICE + EML32NICE appraisals
- L01FF01nivolumabAntineoplastic and immunomodulating agents · source: NICE + EML25NICE appraisals
- L01FF05atezolizumabAntineoplastic and immunomodulating agents · source: NICE + EML11NICE appraisals
- L01FG01bevacizumabAntineoplastic and immunomodulating agents · source: NICE + EML11NICE appraisals
- L01EL01ibrutinibAntineoplastic and immunomodulating agents · source: NICE + EML9NICE appraisals
- L01FC01daratumumabAntineoplastic and immunomodulating agents · source: NICE + EML9NICE appraisals
- L01FF03durvalumabAntineoplastic and immunomodulating agents · source: NICE + EML8NICE appraisals
- L04AB04adalimumabAntineoplastic and immunomodulating agents · source: NICE + EML7NICE appraisals
Daftar lengkap
Semua Prioritas 1
65obat cocok
| ATC | Nama generik | Kelas | NICE | EML | Fornas | e-Kat | Source combination | HTA priority |
|---|---|---|---|---|---|---|---|---|
| L01FF02 | pembrolizumab | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L01FF01 | nivolumab | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L01FF05 | atezolizumab | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L01FG01 | bevacizumab | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L01EL01 | ibrutinib | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L01FC01 | daratumumab | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L01FF03 | durvalumab | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L04AB04 | adalimumab | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| A10BK01 | dapagliflozin | Alimentary tract and metabolism | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| A10BK03 | empagliflozin | Alimentary tract and metabolism | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L01EL03 | zanubrutinib | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L02BB04 | enzalutamide | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L01EB04 | osimertinib | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L01EC02 | dabrafenib | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L01FF06 | cemiplimab | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L01FX07 | blinatumomab | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L03AB10 | peginterferon alfa-2b | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L04AB02 | infliximab | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| L04AC05 | ustekinumab | Antineoplastic and immunomodulating agents | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
| A10BK02 | canagliflozin | Alimentary tract and metabolism | ● | ● | ○ | ○ | NICE + EML | Prioritas 1 |
Menampilkan 1–20 dari 65 obat
1 / 4